Systemic combining inflammatory score (SCIS): a new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer.
Bladder cancer (BC)
immune system
inflammation
outcomes
prognosis
Journal
Translational andrology and urology
ISSN: 2223-4691
Titre abrégé: Transl Androl Urol
Pays: China
ID NLM: 101581119
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
entrez:
15
3
2021
pubmed:
16
3
2021
medline:
16
3
2021
Statut:
ppublish
Résumé
An accurate and early diagnosis of bladder cancer (BC) is essential to offer patients the most appropriate treatment and the highest cure rate. For this reason, patients need to be best stratified by class and risk factors. We aimed to develop a score able to better predict cancer outcomes, using serum variables of inflammation. A total of 1,510 high-risk non-muscle invasive bladder cancer (NMIBC) patients were included in this retrospective observational study. Patients with pathologically proven T1 HG/G3 at first TURBT were included. Systemic combined inflammatory score (SCIS) was calculated according to systemic inflammatory markers (SIM), modified Glasgow prognostic score (mGPS), and prognostic nutritional index (PNI) dichotomized (final score from 0 to 3). After 48 months of follow-up (IQR 40.0-73.0), 727 patients recurred (48.1%), 485 progressed (32.1%), 81 died for cancer (7.0%), and 163 died for overall causes (10.8%). Overall, 231 (15.3%) patients had concomitant Cis, 669 (44.3%) patients had multifocal pathology, 967 (64.1%) patients had tumor size >3 cm. Overall, 357 (23.6%) patients received immediate-intravesical therapy, 1,356 (89.8%) received adjuvant intravesical therapy, of which 1,382 (91.5%) received BCG, 266 (17.6%) patients received mitomycin C, 4 (0.5%) patients received others intravesical therapy. Higher SCIS was independently predictive of recurrence (hazard ratio HR 1.5, 1.3 and 2.2) and cancer specific mortality for SCIS 0 and 3 (HR: 1.61 and 2.3), and overall mortality for SCIS 0 and 3 (HR: 2.4 and 3.2). Conversely, SCIS was not associated with a higher probability of progression. The inclusion of the SCIS in clinical practice is simple to apply and can help improve the prediction of cancer outcomes. It can identify patients with high-grade BC who are more likely to experience disease mortality.
Sections du résumé
BACKGROUND
BACKGROUND
An accurate and early diagnosis of bladder cancer (BC) is essential to offer patients the most appropriate treatment and the highest cure rate. For this reason, patients need to be best stratified by class and risk factors. We aimed to develop a score able to better predict cancer outcomes, using serum variables of inflammation.
METHODS
METHODS
A total of 1,510 high-risk non-muscle invasive bladder cancer (NMIBC) patients were included in this retrospective observational study. Patients with pathologically proven T1 HG/G3 at first TURBT were included. Systemic combined inflammatory score (SCIS) was calculated according to systemic inflammatory markers (SIM), modified Glasgow prognostic score (mGPS), and prognostic nutritional index (PNI) dichotomized (final score from 0 to 3).
RESULTS
RESULTS
After 48 months of follow-up (IQR 40.0-73.0), 727 patients recurred (48.1%), 485 progressed (32.1%), 81 died for cancer (7.0%), and 163 died for overall causes (10.8%). Overall, 231 (15.3%) patients had concomitant Cis, 669 (44.3%) patients had multifocal pathology, 967 (64.1%) patients had tumor size >3 cm. Overall, 357 (23.6%) patients received immediate-intravesical therapy, 1,356 (89.8%) received adjuvant intravesical therapy, of which 1,382 (91.5%) received BCG, 266 (17.6%) patients received mitomycin C, 4 (0.5%) patients received others intravesical therapy. Higher SCIS was independently predictive of recurrence (hazard ratio HR 1.5, 1.3 and 2.2) and cancer specific mortality for SCIS 0 and 3 (HR: 1.61 and 2.3), and overall mortality for SCIS 0 and 3 (HR: 2.4 and 3.2). Conversely, SCIS was not associated with a higher probability of progression.
CONCLUSIONS
CONCLUSIONS
The inclusion of the SCIS in clinical practice is simple to apply and can help improve the prediction of cancer outcomes. It can identify patients with high-grade BC who are more likely to experience disease mortality.
Identifiants
pubmed: 33718065
doi: 10.21037/tau-20-1272
pii: tau-10-02-626
pmc: PMC7947442
doi:
Types de publication
Journal Article
Langues
eng
Pagination
626-635Informations de copyright
2021 Translational Andrology and Urology. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tau-20-1272). The authors have no conflicts of interest to declare.
Références
Urol Oncol. 2019 Mar;37(3):179.e19-179.e28
pubmed: 30580906
World J Urol. 2019 Mar;37(3):507-514
pubmed: 29992381
Medicine (Baltimore). 2018 Nov;97(48):e13218
pubmed: 30508902
Ann Surg Treat Res. 2014 Jun;86(6):309-13
pubmed: 24949322
Clin Genitourin Cancer. 2018 Dec;16(6):445-452
pubmed: 30077463
J Urol. 2005 Apr;173(4):1108-11
pubmed: 15758711
Onco Targets Ther. 2017 Nov 21;10:5541-5550
pubmed: 29200869
Pancreatology. 2015 Nov-Dec;15(6):688-93
pubmed: 26500167
Cancer Med. 2020 Jun;9(11):4014-4025
pubmed: 32216043
J Autoimmun. 2010 May;34(3):J258-65
pubmed: 20042314
J Cancer. 2018 Oct 20;9(22):4250-4254
pubmed: 30519326
J Urol. 2009 Nov;182(5):2195-203
pubmed: 19758621
World J Urol. 2020 Jan;38(1):143-150
pubmed: 30993426
Urol Oncol. 2018 Jan;36(1):8.e17-8.e24
pubmed: 28947304
Ann Surg Oncol. 2016 Dec;23(Suppl 5):1039-1047
pubmed: 27660257
Br J Cancer. 2003 Sep 15;89(6):1028-30
pubmed: 12966420
Br J Cancer. 2007 Nov 5;97(9):1266-70
pubmed: 17923866
Eur Urol Focus. 2018 Jul;4(4):472-480
pubmed: 30172757
Br J Cancer. 2006 Mar 13;94(5):637-41
pubmed: 16479253
Clin Chim Acta. 2018 Nov;486:303-310
pubmed: 30138620
Eur Urol. 2017 Jan;71(1):96-108
pubmed: 27370177
Eur Urol Oncol. 2018 Oct;1(5):403-410
pubmed: 31158079
Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7
pubmed: 16442208
Clin Genitourin Cancer. 2014 Aug;12(4):270-7
pubmed: 24332507
Medicine (Baltimore). 2016 May;95(18):e3539
pubmed: 27149460
Medicine (Baltimore). 2015 Oct;94(42):e1861
pubmed: 26496339
Clin Genitourin Cancer. 2016 Apr;14(2):176-82
pubmed: 26444918
Expert Rev Anticancer Ther. 2018 Oct;18(10):973-980
pubmed: 30081681